Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | Director · President and CEO | March 16, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date March 16, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,150,599 |
Reported balance
After 2026-03-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-16 · Sale · Disposed 47,763 · Balance 5,150,599 F1: 1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: 3. Includes 12,500 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 856,044 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 856,044 F3: Securities held in the name of the RTC 2019 Trust dated October 1, 2019. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 856,044 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 856,044 F4: Securities held in the name of the JEC 2019 Trust dated October 1, 2019. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,201,108 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,201,108 F5: Securities held in the name of the Chang 2006 Family Trust |
Filing footnotes · ownership attribution and instrument terms
F1: 1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: 3. Includes 12,500 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program.
F3: Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
F4: Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
F5: Securities held in the name of the Chang 2006 Family Trust
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kite Pharma, Inc.
Report date October 03, 2017 · Filed October 05, 2017
Section 16 reporting ended · disclosed 2017-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-10-03 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2017-09-11 · Gift · Disposed 375 · Balance 57,048 Row 2 · 2017-09-12 · Gift · Disposed 1,041 · Balance 56,007 Row 3 · 2017-09-13 · Gift · Disposed 157 · Balance 55,850 Row 4 · 2017-09-20 · Gift · Disposed 570 · Balance 55,280 Row 5 · 2017-10-03 · Other · Disposed 16,605 · Balance 38,675 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was validly tendered for $180 per share in cash, without interest and subject to any required withholding of taxes. Row 6 · 2017-10-03 · Disposition to issuer · Disposed 38,675 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person. F4: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio"). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.89 · Expires 2024-06-05 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-10-03 · Disposition to issuer · Disposed 116,750 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option. F5: This option provided for 25% vesting on June 2, 2015, and vesting thereafter in 36 equal monthly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.89 · Expires 2024-06-05 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-10-03 · Disposition to issuer · Disposed 56,250 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F5: This option provided for 25% vesting on June 2, 2015, and vesting thereafter in 36 equal monthly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.96 · Expires 2024-12-23 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-10-03 · Disposition to issuer · Disposed 51,563 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option. F8: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.96 · Expires 2024-12-23 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-10-03 · Disposition to issuer · Disposed 23,437 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F8: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.87 · Expires 2025-12-16 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2017-10-03 · Disposition to issuer · Disposed 28,919 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option. F9: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.87 · Expires 2025-12-16 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2017-10-03 · Disposition to issuer · Disposed 37,181 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F9: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.09 · Expires 2026-12-21 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2017-10-03 · Disposition to issuer · Disposed 90,600 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F10: This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was validly tendered for $180 per share in cash, without interest and subject to any required withholding of taxes.
F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person.
F4: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio").
F5: This option provided for 25% vesting on June 2, 2015, and vesting thereafter in 36 equal monthly installments.
F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option.
F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio.
F8: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments.
F9: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments.
F10: This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2018 Filed Oct 17, 2018 21:30 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | ConversionCommon Stock | 29,946 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055374 · doc4.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,101,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: Securities held in the name of the Chang 2006 Family Trust. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 21:30 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | PurchaseCommon Stock | 40,000 | $18.00 | $720,000.00 |
DisclosureSEC source: 0001209191-18-055374 · doc4.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,995,625 Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:12 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 90,600 | Not disclosed Strike: $46.09 | Not disclosed |
DisclosureSEC source: 0001209191-17-056218 · doc4.xml · derivative · entry 13 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,600 shares Expires 2026-12-21 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F10 · derivative.exercise_date: This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:12 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 37,181 | Not disclosed Strike: $63.87 | Not disclosed |
DisclosureSEC source: 0001209191-17-056218 · doc4.xml · derivative · entry 12 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,181 shares Expires 2025-12-16 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F9 · derivative.exercise_date: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:12 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 28,919 | $116.13 Strike: $63.87 | $3,358,363.47 |
DisclosureSEC source: 0001209191-17-056218 · doc4.xml · derivative · entry 11 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,919 shares Expires 2025-12-16 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6 · price: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option. F9 · derivative.exercise_date: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:12 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 23,437 | Not disclosed Strike: $51.96 | Not disclosed |
DisclosureSEC source: 0001209191-17-056218 · doc4.xml · derivative · entry 10 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,437 shares Expires 2024-12-23 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F8 · derivative.exercise_date: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:12 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 51,563 | $128.04 Strike: $51.96 | $6,602,126.52 |
DisclosureSEC source: 0001209191-17-056218 · doc4.xml · derivative · entry 9 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,563 shares Expires 2024-12-23 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6 · price: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option. F8 · derivative.exercise_date: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:12 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 56,250 | Not disclosed Strike: $6.89 | Not disclosed |
DisclosureSEC source: 0001209191-17-056218 · doc4.xml · derivative · entry 8 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,250 shares Expires 2024-06-05 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F5 · derivative.exercise_date: This option provided for 25% vesting on June 2, 2015, and vesting thereafter in 36 equal monthly installments. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:12 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 116,750 | $173.11 Strike: $6.89 | $20,210,592.50 |
DisclosureSEC source: 0001209191-17-056218 · doc4.xml · derivative · entry 7 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 116,750 shares Expires 2024-06-05 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6 · price: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option. F5 · derivative.exercise_date: This option provided for 25% vesting on June 2, 2015, and vesting thereafter in 36 equal monthly installments. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:12 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerCommon Stock | 38,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-056218 · doc4.xml · nonDerivative · entry 6 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3 · shares: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person. F4 · shares: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio"). F4 · price: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio"). Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:12 UTC | Kite Pharma, Inc. KITE · Entity 172664 | OtherCommon Stock | 16,605 | $180.00 | $2,988,900.00 |
DisclosureSEC source: 0001209191-17-056218 · doc4.xml · nonDerivative · entry 5 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,675 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · shares: Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was validly tendered for $180 per share in cash, without interest and subject to any required withholding of taxes. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 21:40 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 7,927 | $179.66 | $1,424,195.74 |
DisclosureSEC source: 0001209191-17-054196 · doc4.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,423 F2 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 21:40 UTC | Kite Pharma, Inc. KITE · Entity 172664 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-054196 · doc4.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,350 F1 · balance_after: Includes 185 shares acquired under the 2014 Employee Stock Purchase Plan on August 18, 2017. Read SEC document |
| September 20, 2017 Filed Oct 5, 2017 20:12 UTC | Kite Pharma, Inc. KITE · Entity 172664 | GiftCommon Stock | 570 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056218 · doc4.xml · nonDerivative · entry 4 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,280 Read SEC document |
| September 13, 2017 Filed Oct 5, 2017 20:12 UTC | Kite Pharma, Inc. KITE · Entity 172664 | GiftCommon Stock | 157 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056218 · doc4.xml · nonDerivative · entry 3 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,850 Read SEC document |
| September 12, 2017 Filed Oct 5, 2017 20:12 UTC | Kite Pharma, Inc. KITE · Entity 172664 | GiftCommon Stock | 1,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056218 · doc4.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,007 Read SEC document |
| September 11, 2017 Filed Oct 5, 2017 20:12 UTC | Kite Pharma, Inc. KITE · Entity 172664 | GiftCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056218 · doc4.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,048 Read SEC document |
| May 01, 2017 Filed May 3, 2017 18:06 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.89 | $0.00 |
DisclosureSEC source: 0001209191-17-029753 · doc4.xml · derivative · entry 5 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,000 Underlying: Common Stock · 20,000 shares Expires 2024-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the 300,000 shares subject to the stock option vested and became exercisable on June 2, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| May 01, 2017 Filed May 3, 2017 18:06 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 300 | $83.36 | $25,008.00 |
DisclosureSEC source: 0001209191-17-029753 · doc4.xml · nonDerivative · entry 4 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,165 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.27 to $83.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 01, 2017 Filed May 3, 2017 18:06 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 5,905 | $82.60 | $487,753.00 |
DisclosureSEC source: 0001209191-17-029753 · doc4.xml · nonDerivative · entry 3 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,465 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.25 to $83.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 01, 2017 Filed May 3, 2017 18:06 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 13,795 | $81.84 | $1,128,982.80 |
DisclosureSEC source: 0001209191-17-029753 · doc4.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,370 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.26 to $82.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 01, 2017 Filed May 3, 2017 18:06 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Exercise / conversionCommon Stock | 20,000 | $6.89 | $137,800.00 |
DisclosureSEC source: 0001209191-17-029753 · doc4.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 16:17 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.89 | $0.00 |
DisclosureSEC source: 0001209191-17-024746 · doc4.xml · derivative · entry 8 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,000 Underlying: Common Stock · 20,000 shares Expires 2024-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 25% of the 300,000 shares subject to the stock option vested and became exercisable on June 2, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 16:17 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 700 | $83.66 | $58,562.00 |
DisclosureSEC source: 0001209191-17-024746 · doc4.xml · nonDerivative · entry 7 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,165 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.42 to $83.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 16:17 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 8,697 | $82.60 | $718,372.20 |
DisclosureSEC source: 0001209191-17-024746 · doc4.xml · nonDerivative · entry 6 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,865 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.29 to $83.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 16:17 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 3,549 | $82.00 | $291,018.00 |
DisclosureSEC source: 0001209191-17-024746 · doc4.xml · nonDerivative · entry 5 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,562 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.30 to $82.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 16:17 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 2,424 | $80.44 | $194,986.56 |
DisclosureSEC source: 0001209191-17-024746 · doc4.xml · nonDerivative · entry 4 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,111 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.07 to $80.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 16:17 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 3,939 | $79.63 | $313,662.57 |
DisclosureSEC source: 0001209191-17-024746 · doc4.xml · nonDerivative · entry 3 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,535 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.07 to $80.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 16:17 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 691 | $78.53 | $54,264.23 |
DisclosureSEC source: 0001209191-17-024746 · doc4.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,474 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.05 to $78.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 16:17 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Exercise / conversionCommon Stock | 20,000 | $6.89 | $137,800.00 |
DisclosureSEC source: 0001209191-17-024746 · doc4.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 06:08 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Exercise / conversionEmployee Stock Option(Right to Buy) · Derivative | 60,000 | $0.00 Strike: $6.89 | $0.00 |
DisclosureSEC source: 0000899243-17-005893 · doc4.xml · derivative · entry 4 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,000 Underlying: Common Stock · 60,000 shares Expires 2024-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the 300,000 shares subject to the stock option vested and became exercisable on June 2, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 06:08 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 4,735 | $79.71 | $377,426.85 |
DisclosureSEC source: 0000899243-17-005893 · doc4.xml · nonDerivative · entry 3 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,165 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.60 to $79.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 06:08 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 55,265 | $79.11 | $4,372,014.15 |
DisclosureSEC source: 0000899243-17-005893 · doc4.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,900 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.60 to $79.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 06:08 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Exercise / conversionCommon Stock | 60,000 | $6.89 | $413,400.00 |
DisclosureSEC source: 0000899243-17-005893 · doc4.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 242 shares acquired under the 2014 Employee Stock Purchase Plan on February 17, 2017. Read SEC document |
| December 22, 2016 Filed Dec 27, 2016 17:28 UTC | Kite Pharma, Inc. KITE · Entity 172664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 90,600 | $0.00 Strike: $46.09 | $0.00 |
DisclosureSEC source: 0001209191-16-156833 · doc4.xml · derivative · entry 2 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,600 Underlying: Common Stock · 90,600 shares Expires 2026-12-22 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on the first anniversary of the grant date, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| December 22, 2016 Filed Dec 27, 2016 17:28 UTC | Kite Pharma, Inc. KITE · Entity 172664 | GrantCommon Stock | 24,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156833 · doc4.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,923 Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 16:50 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 1,788 | $50.86 | $90,937.68 |
DisclosureSEC source: 0001209191-16-156547 · doc4.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · EVP, R&D, Chief Medical Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,123 F1 · kind: Shares were sold to cover the tax obligation that occurred upon the vesting of an RSU. F2 · balance_after: Includes 821 shares acquired under the 2014 Employee Stock Purchase Plan (the "ESPP") on February 19, 2016 and 686 shares acquired under the ESPP on August 19, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.